Share price of Lupin gained 5.25% to Rs 1021 against previous close of Rs 970.10 on BSE

Lupin Pharma has sold the entire stake (99.82%) in its Japanese subsidiary Kyowa to Unison's entity Plutus Ltd, Japan, for an enterprise value of $300 million, subject to closing adjustments

The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019

The deal proceeds will be utilised to strengthen Lupin's balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets, says Lupin CEO Vinita Gupta

Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year

Homegrown pharma major Lupin on September 25 announced appointment of Jon Stelzmiller as the President of its US specialty business.

Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.

A big transformation is happening in the global generic pharmaceutical industry. As a result, stocks of most major drug companies have done badly in the past one year.

Enbrel had global brand sales of approximately $11.6 billion for the 12 months ending December 31, 2017, according to IQVIA.

Margin erosion and regulatory hurdles are hitting Indian pharma companies hard in their biggest market.

Analysts see it as a good opportunity for Lupin but feel the company may need to wait for say another two years or so for benefits to accrue since they may first need to invest in certain things, putting additional pressure on the company.

The acquisition of Symbiomix and the 'Solosec' franchise will help Lupin expand its women's health specialty business. Lupin will pay $50 million upfront and the remaining $100 million over the next five years.

The US-based global CEO of Lupin, Vinita Gupta, tells P.B. Jayakumar about the crises Indian drug companies are facing in the US.

His efforts have led to a positive impact on the lives of 2.8 million families in 3,463 villages across the country, the company said.

An air of urgency has been visible at the Mumbai headquarters of the second-largest Indian pharmaceutical company by sales, Lupin Ltd, for the past three to four years.

I have always been inherently passionate and ambitious about work and family, and perhaps it has a lot to do with my genes. Growing up, it was often hard to separate the family from the business of Lupin.

Reliance Foundation Chairperson Nita Ambani has been named the most powerful businesswoman in Asia by Forbes, leading a list of 50 women leaders from the region that includes eight from India.